探讨兴奋性氨基酸受体拮抗剂治疗中度阿尔茨海默病的临床疗效  

To Explore the Clinical Efficacy of Excitatory Amino Acid Receptor Antagonists in the Treatment of Moderate Alzheimer’s Disease

作　　者：马征 王辰龙 MA Zheng;WANG Chenlong(Department of Neurology,Civil AviationGeneral Hospital,Beijing 100123,China)

机构地区：[1]民航总医院神经内科

出　　处：《中国继续医学教育》2019年第18期118-120,共3页China Continuing Medical Education

摘　　要：目的分析采用兴奋性氨基酸受体拮抗剂替换多奈哌齐治疗对中度阿尔茨海默病患者的临床疗效和安全性。方法选择我院于2016年10月—2018年10月收治的中度阿尔茨海默病患者80例作为研究对象。按照治疗手段的不同,将其分为对照组(40例,采用多奈哌齐治疗)和观察组(40例,采用兴奋性氨基酸受体拮抗剂治疗)。结果观察组患者好转率为85.0%,高于对照组好转率的72.5%,同时观察组患者的MMSE评分为(19.56±1.51)分,高于对照组MMSE评分的(17.25±3.42)分;观察组患者的ADL评分为(82.12±15.42)分,高于对照组ADL评分的(62.36±24.12)分,差异均有统计学意义(P<0.05)。但两组并发症发生率比较,差异无统计学意义(P>0.05)。结论在对中度阿尔茨海默病患者实施临床治疗时,将兴奋性氨基酸受体拮抗剂替换多奈哌齐治疗,可显著提升治疗效果,同时治疗安全性较好,有较高临床使用价值。Objective To analyze the clinical efficacy and safety of the replacement of donepezil with excitatory amino acid receptor antagonist in the treatment of moderate Alzheimer's disease. Methods 80 patients with moderate Alzheimer's disease admitted to our hospital from October 2016 to October 2018 were selected as the subjects of study. According to the different treatment methods, they were divided into control group (40 cases treated with donepezil) and observation group (40 cases treated with excitatory amino acid receptor antagonist). Results The improvement rate of the observation group was 85.0%, which was higher than 72.5% of the control group. At the same time, the MMSE score of the observation group was (19.56±1.51) points, which was higher than that of the control group (17.25±3.42) points. The ADL score of the observation group was (82.12±15.42) points, which was higher than that of the control group (62.36±24.12) points. The difference was statistically significant (P < 0.05). However, there was no significant difference in the incidence of complications between the two groups (P > 0.05). Conclusion In the clinical treatment of moderate Alzheimer's disease, the replacement of donepezil with excitatory amino acid receptor antagonist can significantly improve the therapeutic effect, while the treatment is safe and has high clinical value.

关 键 词：兴奋性氨基酸受体拮抗剂 多奈哌齐 中度阿尔茨海默病 MMSE评分 生活功能 疗效 

分 类 号：R749[医药卫生—神经病学与精神病学]